News

Public · Published

Citigroup maintains West Pharmaceutical Servs at Buy, raises price target to $494 from $412

Citigroup kept its Buy rating on West Pharmaceutical Services and raised its price target to $494 from $412, a 19.9% increase. That target implies 19.7% upside from the October 30 close of $412.62.

Published:

Updated:

What happened

Citigroup kept its Buy rating on West Pharmaceutical Services and raised its price target to $494 from $412, a 19.9% increase. That target implies 19.7% upside from the October 30 close of $412.62.

Confirmed

Global impact / market context

A higher price target signals that this analyst expects the stock to be worth more than before. Investors who follow ratings may treat it as a sign of confidence in the company's future profit and sales growth.

Analyst inference

Other recent analyst notes set targets between $480 and $500, so Citigroup's $494 sits inside that range. This suggests several analysts share a similar view on the stock, rather than one firm standing alone.

Analyst inference

What to watch

  1. Citigroup maintained a Buy rating, which means it still expects the stock to perform well for investors over time. Confirmed
  2. Watch whether other analysts change their price targets, since a cluster of higher targets can shift how investors position money in the stock. Analyst inference
  3. Watch the company's next financial results, because actual sales and profit could confirm or challenge these analyst expectations. Analyst inference

Evidence

  • Original source link unavailable